belitebio.com
Bize Ulaşın
Şirket hakkında
Clinical stage biopharma targeting untreatable age-related metabolic disease. Developed from our RBP4 platform technology, Belite Bio™'s lead candidate LBS-008 is in a Phase I clinical trial for dry age-related macular degeneration and its juvenile form, Stargardt disease. LBS-008 has received Orphan Drug Designation in the US and EU, as well as Rare Pediatric Disease Designation in the US.
US
Bilinmeyen
Doğrulanmamış şirket
iş şeffaflığı
- Şirket bilgileri doğrulanmadı
- Müşterilerinden inceleme isteyin
- Olumsuz yorumlara cevap vermedi